MicroRNA-based approach to treating malignant pleural mesothelioma
AssigneeAsbestos Diseases Research Foundation
InventorsGlen Reid, Nico van Zandwijk
Life of this patent
Estimating the term…
Abstract
The invention relates to microRNA mimics, corresponding to the miR-15/107 family, and to methodology for using microRNA mimics to treat malignant pleural mesothelioma (MPM) by restoring regulation of the expression of target genes of the miR-15/107 family in MPM tumor cells.
Claims7
A double-stranded microRNA mimic for the treatment of malignant pleural mesothelioma (MPM), wherein the microRNA mimic comprises:
- (a) a consensus sequence of the miR-15/107 family, wherein the consensus sequence comprises a sequence selected from the group consisting of SEQ ID NOS:
- 11-14;
- and (b) a passenger strand.
A double-stranded microRNA mimic for the treatment of malignant pleural mesothelioma (MPM), wherein the microRNA mimic comprises:
- (a) a consensus sequence of the miR-15/107 family, wherein the consensus sequence contains AGCAGC at positions 2-7 at the 5′ end but is different from the natural sequence of any miR-15/107 family member;
- and (b) a passenger strand, wherein the passenger strand comprises a sequence selected from the group consisting of SEQ ID NOS:
- 15-18.
A double-stranded microRNA mimic for the treatment of malignant pleural mesothelioma (MPM), wherein the microRNA mimic comprises:
- (a) a consensus sequence of the miR-15/107 family, wherein the consensus sequence comprises a sequence that differs from any one of SEQ ID NOS:
- 11-14 by one or more nucleotides that are modified therefrom;
- and (b) a passenger strand.
Dependencies are inferred from the claim text.